Background: The prevalence and molecular characteristics of defective mismatch repair epithelial ovarian cancers in the Japanese population have scarcely been investigated. Methods: Immunohistochemistry for mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2) was performed in formalin-fixed paraffin-embedded sections prepared from resected primary epithelial ovarian cancers in patients who underwent oophorectomy at our institution between April 2005 and September 2014. Genetic and/or epigenetic alterations of the mismatch repair genes were investigated in patients with loss of any mismatch repair proteins in the tumor. Results: There were 305 patients with a median age of 54 years (range, 18-83 years). Loss of expression in the ovarian tumor of one or more mismatch repair proteins was observed in 3 of the 305 patients (0.98%): 2 patients MLH1/PMS2 loss and 1 patient showed MSH2/MSH6 loss. Genetic testing of these three patients failed to reveal any pathogenic germline mutations of MLH1 or MSH2. One patient with MLH1/PMS2 loss showed hypermethylation of the promoter region of MLH1. Somatic mutations were found in each of the alleles of MLH1 (c.545dupG and deletion of exons 2-19) in the other patient with MLH1/PMS2 loss. In the patient with MSH2/MSH6 loss, two somatic mutations were detected in MSH2 (c.229_230delAG and c.1861C>T), although we could not determine whether these mutations were biallelic or not. Conclusions: The prevalence of defective mismatch repair epithelial ovarian cancer in the Japanese hospital-based population was extremely low. Molecular mechanism involved in such defective mismatch repair ovarian cancers seems to be epigenetic events through MLH1 promotor hypermethylation or somatically mutated mismatch repair genes without germline mismatch repair mutation.
Introduction
Defective mismatch repair (dMMR) tumors leads to abnormal functions of the MMR proteins due to either genetic (1) or epigenetic (2) events, resulting in the accumulation of errors during DNA replication, especially in repetitive sequences known as microsatellites. Consequently, the hallmarks of dMMR tumors are loss of MMR protein expression and/or high-level (high-frequency) microsatellite instability (MSI-H) (3) .
Recently, pembrolizumab, which is an anti-PD-1 antibody, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with various types of cancers showing MMR protein loss or MSI-H, based on the results of clinical trials (4) . This drug is expected to improve the overall survival in the subset of cancer patients with loss of MMR protein expression and/or MSI-H in the tumor (4) . Therefore, the evaluation of cancer patients for the expression status of the MMR proteins and/or MSI in the tumor will be required to select patients who will benefit from the treatment with anti-PD-1 antibody. Numerous researchers have reported the prevalence of tumors showing loss of MMR protein expression and/or MSI among patients with colorectal cancer (5, 6 ) and endometrial cancer (7, 8) , since these cancers are known to be frequently associated with Lynch syndrome (LS), an inherited autosomal dominant disease caused by deleterious germline mutations in one of the MMR genes, namely, MLH1, MSH2, MSH6 and PMS2, and more recently recognized, deletion of the EPCAM gene located upstream of MSH2 (9) .
Epithelial ovarian cancer is also known to be one of the important LS-associated tumors as documented in the revised Bethesda guidelines (10) , although it has not been described in the revised Amsterdam Criteria (11) . In addition, some studies performed in the Western countries have reported the existence of a small, but significant proportion of dMMR tumors in selected (12, 13) or nonselected (14-16) case series of epithelial ovarian cancers. Therefore, screening for MMR protein loss and/or MSI-H is also indicated in patients with epithelial ovarian cancer, for identification of those patients who would benefit from the treatment with anti-PD-1 antibody, that is, for personalized cancer treatment.
Immunohistochemistry (IHC) for MMR protein expression seems to be increasingly replacing MSI testing as a screening method for dMMR colorectal cancer (17) , as well as for other LS-associated tumors, including ovarian cancers (12) (13) (14) (15) (16) . The concordance rate of the results of IHC and MSI testing is more than 90% in the case of colorectal (18) and endometrial cancer (19) , while such comparisons have not yet been reliably performed in patient with epithelial ovarian cancer. IHC offers the distinct advantages of being cost-effective and of being widely available at many institutions as compared to MSI testing. In addition, another advantage of IHC is that the MMR gene that is likely to show genetic/epigenetic alterations can be pinpointed (20) .
Hypermethylation of the MLH1 promoter region is a wellknown epigenetic mechanism underlying dMMR in various cancers, including epithelial ovarian cancer (21, 22) . In LS, when the remaining wild-type allele of the causative MMR gene along with deleterious (pathogenic) germline mutation is somatically mutated, the MMR system loses its function, promoting cancer development (23) . Recently, somatic mutations in the MMR genes in the absence of germline mutations have been revealed to be a novel mechanism responsible for the occurrence of dMMR tumors in a subset of patients initially suspected as having LS (24) (25) (26) . This condition is termed 'Lynch-like syndrome' or 'Lynch syndrome mimic', and while its occurrence has been extensively examined in colorectal cancers and endometrial cancers, it has scarcely been investigated in other LS-associated tumors, including epithelial ovarian cancer. To the best of our knowledge, the proportion of dMMR ovarian cancers in light of at least these three molecular mechanisms has not been investigated yet.
We conducted this study to clarify the prevalence of dMMR epithelial ovarian cancers among a Japanese hospital-based population, through universal tumor screening (UTS) using IHC for determining MMR protein expression, since such data are scarce in Japan, in addition, we explored the molecular mechanisms underlying dMMR in epithelial ovarian cancers.
Material and methods

Ethical considerations
This study was conducted with the approval of the local ethics committee of Saitama Medical Center (Nos 924, 925 and 926) and Saitama Medical University (Nos 592 and 747). For the genetic testing of the MMR genes, informed consent was obtained from each patient.
Patients
Newly diagnosed epithelial ovarian cancer patients who underwent respective surgery between April 2005 and September 2014 at our institution were enrolled in this study. The demographic and clinicopathological data, as also the personal/family histories of the patients, were obtained from the medical charts. The histological diagnoses and tumor differentiation grades were determined according to the classification of the General Rules for Clinical and Pathological Management of Ovarian Tumor, Fallopian Tube Cancer, and Primary Peritoneal Cancer in Japan (27) . All tumors were staged according to the International Federation of Gynecology and Obstetrics criteria (28) .
IHC for MMR proteins
IHC was performed as previously described (5) . Briefly, 4-μm-thick sections prepared from formalin-fixed paraffin-embedded (FFPE) specimens of the ovarian tumors were stained for the four MMR proteins (MLH1, MSH2, MSH6 and PMS2) using a Staining Automat (BOND III, Leica Biosystems Melbourne Pvt. Ltd, Melbourne, Australia), in accordance with the manufacturer's protocol. The primary antibodies used for detecting the MMR proteins were anti-hMLH1 antibody (clone ES05, Leica Biosystems Newcastle Ltd, Newcastle, UK, 1:100), anti-hMSH2 antibody (clone 25D12, Leica Biosystems Newcastle Ltd, 1:100), anti-hMSH6 antibody (clone PU29, Leica Biosystems Newcastle Ltd, 1:70) and antihPMS2 antibody (clone M0R4G, Leica Biosystems Newcastle Ltd, 1:40). The MMR proteins are known to be localized in the nuclei. The absence of nuclear staining in the tumor cells was judged as reflecting loss of MMR protein expression.
The immunohistochemical evaluations were performed independently by two investigators (T.T. and J.T.) without prior information about the clinicopathological features of the patients.
DNA extraction and microdissection
DNA was extracted from leukocytes and 10-μm-thick FFPE sections of normal ovarian mucosa or cancer tissue. Prior to the DNA extraction from the FFPE tissue specimens, laser-assisted microdissection using a Leica LMD 7000 system (Leica Microsystems GmbH, Wetzlar, Germany) was conducted to collect the cancerous and non-cancerous tissues. DNA from the leukocytes was extracted using the QIAamp DNA Mini kit (QIAGEN, Hilden, Germany), while that from the FFPE sections was extracted using the QIAamp DNA FFPE Tissue Kit (QIAGEN).
MSI testing
The testing for MSI was conducted using the MSI Analysis System, Version 1.2 (Promega Corporation, Madison, WI, US), which evaluates the MSI status of five mononucleotide microsatellite markers, BAT25, BAT26, NR21, NR22 and NR24, all of which are recommended by the revised Bethesda guidelines (10) . After the marker genes were amplified, the products were subjected to fragment analysis using the Applied Biosystems 3500 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) and GeneMapper software (Applied Biosystems). When two or more markers showed altered numbers of repeats in the markers, we classified the cancer as showing MSI-H.
Sanger sequencing
Sanger sequencing was performed using amplified DNA fragments, the indicated primers, the BigDye 3.1 cycle sequencing kit (Thermo Fisher Scientific Inc., Waltham, MA, USA) and the ABI 3500 Genetic analyzer (Thermo Fisher Scientific Inc.).
Methylation analysis of the MLH1 gene promoter C-region
When necessary, the methylation analysis of the MLH1 promoter C-region was performed in FFPE specimens of the tumors and normal mucosa, essentially as described previously (5), with slight modification. Bisulfite conversion of the extracted DNA was conducted using the EZ DNA Methylation-Gold™ Kit (ZYMO RESEARCH Corporation, Irvine, CA, USA). The promoter C-region of MLH1 was amplified using the following primers: MLH1C_BS_F02:5′-GGTATTTTTG TTTTTATTGGTTGGA-3′ and MLH1C_BS_R02:5′-CCAATCAAA TTTCTCAACTCTATAAA-3′. Sanger sequencing was conducted using the MLH1C_BS_R02. When only a cytosine residue signal was observed at the CpG sites in the MLH1 promoter C-region, the sample was classified as showing 'hypermethylated'; on the other hand, when only a thymine residue signal was observed at the CpG sites, the sample was classified as 'unmethylated'. Furthermore, samples showing both cytosine and thymidine residues at the CpG sites were categorized as 'heterozygously methylated'.
Detection of germline mutations and copy number variances
Full-sequence analysis of the MMR genes in the germline, extracted from the blood or FFPE specimens of normal mucosa, was performed using the direct sequencing method, as previously described (5). Analysis of the MLH1 and MSH2 genes was performed according to the protocol provided by Thermo Fisher Scientific (Development of a resequencing Workflow for variant analysis of MLH1 and MSH2).
When no deleterious (pathogenic) mutations were detected by Sanger sequencing, a multiplex ligation-dependent probe amplification (MLPA) analysis was performed for detecting copy number variances of the exons of the MLH1, MSH2 and EPCAM genes using the Salsa ® MLPA ® kit P-003 (MRC-Holland, Amsterdam, Netherlands) and Coffalyser.Net software (MRC-Holland).
The identified variants were assessed by the InSiGHT classification criteria (http://insight-group.org/variants/classifications/). Variants categorized into class 4 or class 5 were considered to be pathogenic in the present study.
When no germline MMR mutation was detected in the DNA samples, RNA sequencing was undertaken to search for structural alterations of the MMR gene. After the synthesis of cDNAs with oligo-dT primer using the SuperScript First-strand Synthesis system (Thermo Fisher Scientific, Waltham, MA, USA), the coding DNA sequence regions of the MMR genes were amplified by polymerase chain reaction (PCR) and subjected to library preparation using the Nextera XT Sample Prep kit (Illumina, Santa Clara, USA), in accordance with the manufacturer's protocol. The library was run on the MiSeq sequencer (Illumina). Otherwise, the prepared RNA was transcribed using the reverse transcriptase ReverTraAce (TOYOBO) and the MMR (MLH1 or MSH2) cDNAs were amplified using specific primer sets for each gene. Sanger sequencing analysis was performed for the PCR products.
Results
Patient background data
There were 305 female patients. The median age of the patients was 54 years (range, 18-83 years). When stratified by the age groups, there were 9 (3.0%) patients who were <29 years old, 42 
IHC for MMR proteins, and the clinicopathological and molecular characteristics of dMMR cases
Of the 305 epithelial ovarian cancer patients, 3 (0.98%) patients showed loss of one or more of the MMR proteins in the tumor. Loss of MLH1 and PMS2 was observed in two patients, while loss of MSH2 and MSH6 was observed in one patient (Fig. 1 ). There were no patients showing loss of expression of MSH6 or PMS alone.
The clinicopathological and molecular characteristics of the three patients with dMMR epithelial ovarian cancer are shown in Table 1 . The patients were aged 53, 47 and 42 years old, respectively. The histologic type was exclusively endometrioid adenocarcinoma, accounting for 5.4% of all the 56 patients with endometrioid adenocarcinoma in the patient series. MSI testing of the tumors performed in these three patients revealed MSI-H in the cancer in all.
Analysis of germline mutations and copy number variances
Genetic tests were performed in the three patients with dMMR ovarian cancer. Cases 1 and 2 were tested for the MLH1 gene, since the cancers in these patients showed loss of expression of MLH1 and PMS2. However, neither of these patients showed pathogenic germline mutations or copy number alterations in the MLH1 gene. Case 3, which showed loss of expression of MSH2 and MSH6 in the cancer, was examined for MSH2 gene mutation, however, no pathogenic mutations were identified. MLPA analysis of the MSH2 and EPCAM genes in Case 3 did not reveal any copy number alterations ( Table 1) .
Analysis of somatic events inactivating the MLH1 or MSH2 gene in the cancer tissue Methylation analysis of the MLH1 gene promoter region was performed in Cases 1 and 2. Hypermethylation of the MLH1 gene was observed in the cancer tissue but not in the normal mucosa in Case 1, indicating that the cancer was a sporadic cancer caused by biallelic methylation of the MLH1 gene promoter region ( Supplementary Fig. 1 ). The heterogeneous methylation pattern was observed in the cancer tissue of Case 2 ( Supplementary Fig. 1) .
Next, somatic mutations and copy number alterations of the MLH1 gene in the cancer tissue of Case 2 were analyzed. A pathogenic frameshift mutation, c.545dupG, was detected in the MLH1 gene ( Supplementary Fig. 2 ). In addition, a large deletion of exons 2-19 of the MLH1 gene was detected in the cancer tissue by the MLPA test (Supplementary Fig. 2 ). Since the c.545dupG mutation was located within exon 6 of the MLH1 gene, biallelic inactivation of the MLH1 gene was identified in the cancer tissue of Case 2.
In the Case 3, in which the tumor-lacked MSH2 and MSH6 expressions, two somatic mutations were found; one was a frameshift mutation, c.229_230delAG/p.Ser77Cysfs*4, and the other was a non-sense mutation, c.1861C>T; the mutations resulted in acquisition of the stop codon, TGA, at position 621. Both mutations were established pathogenic mutations (Supplementary Fig. 3 ). Because the DNA extracted from the FFPE specimen of the cancer tissue showed severe fragmentation, and the two somatic mutations detected were located in exons 2 and 12, separated by 66 kb on the chromosome, we could not determine whether these mutations were present in both the alleles or not. MLPA analysis of the cancer tissue in this patient showed no copy number variance in either MSH2 or EPCAM. The molecular characteristics of dMMR in these cases are also summarized in Table 1 .
Discussion
In the present study, the prevalence of dMMR tumors among nonselected cases of epithelial ovarian cancer, identified through UTS using IHC for detecting MMR protein expression in a Japanese hospital-based population, was 0.98%. No pathogenic germline mutations of the MMR genes were detected in any of the dMMR cases, suggesting that there were no patients with LS among the 305 ovarian cancer patients enrolled in this study. It is noteworthy that we identified one case of dMMR epithelial ovarian cancer with MLH1 promoter region hypermethylation and two cases with pathogenic somatic MMR mutations in the absence of the relevant germline mutation.
The prevalence of dMMR tumors among non-selected patients with epithelial ovarian cancers identified through UTS using IHC for detecting MMR protein expression has been reported to range from 2.2% to 3.1% (14-16) in Western countries ( Table 2 ). The prevalence of dMMR epithelial ovarian tumors (0.98%) in the present study seems to be lower than that reported from Western countries. The reasons are unclear, but it could be explained as a simple reflection of ethnic variations in the frequency of alleles that influence dMMR. Concerning the ethnic variations in the prevalence of dMMR colorectal cancers, we recently reported that the prevalence of dMMR of 4.9% in 1 234 colorectal cancer patients in Japan was much lower than that of 12-16% reported from Western countries (5). However, a recent report from Japan (29) showed that the prevalence of dMMR tumors was 3.1% among 129 patients with epithelial ovarian cancers similar to the data of Western countries. To conclude the exact prevalence of dMMR among epithelial ovarian cancers, further collection of data from all over the world is necessary.
We confirmed that all the three cases with loss of MMR protein expression showed MSI-H. According to the findings of previous studies (13) (14) (15) 29) , most tumors with loss of MMR protein expression show MSI-H. This is consistent with our results. The prevalence of dMMR detected by MSI testing (30) (31) (32) tended to be slightly higher than that detected by IHC method (12) (13) (14) (15) (16) in the cases of epithelial ovarian cancer. It may be argued that both IHC and MSI testing should be concomitantly undertaken for dMMR screening in epithelial ovarian cancers. However, there is no report of any largescale comparison of the results of IHC and MSI testing in ovarian cancers. Recent reports (33, 34) indicate that MSI-H is also frequently detected in normal ovaries, probably in association with the normal ovulatory process. Therefore, we believe that IHC may be more reliable for the detection of dMMR than MSI testing for UTS of epithelial ovarian cancers for dMMR.
In the present study, the expression of MLH1/PMS2 was lost in two cases and that of MSH2/MSH6 was lost in the third case. There were no cases with loss of MSH6 or PMS2 alone. In general, the expression pattern of MLH1/PMS2 and MSH2/MSH6 implies the causal gene, MLH1 and MSH2 mutations or hypermethylation, respectively (20) . Based on that principle, the frequency of the causal gene of the dMMR cases in previous studies (Table 2 ) was as follows: MLH1 (13 cases), MSH2 (3 cases), MSH6 (2 cases) and PMS2 (1 case). The reason why MLH1 expression was most frequently lost in ovarian cancer with dMMR is that the MLH1 gene might be hypermethylated in almost cases with loss of MLH1. In addition, Figure 1 . Expression of MMR proteins indicated in the cancer tissue sections from the ovarian cancer patients with dMMR. In cases 1 and 2, loss of MLH1 and PMS2 was observed in the nuclear of cancer cells, while loss of MSH2 and MSH6 was observed in case 3.
Helder-Woolderink et al. (35) summarized that most frequent mutations were MSH2 (47%) and MLH1 (38%) in ovarian cancer associated with LS. After all, MLH1 and MSH2 were major cause of MMR deficiency in epithelial ovarian cancer. Several reports (8, 36) suggested that the MSH6 mutations were more common in endometrial and ovarian cancers as compared with gastrointestinal tract cancers in LS patients. MMR deficiency caused by MSH6 mutations was often missing when MSI test was examined (37) . Consequently, an IHC method can detect dMMR caused by the MSH6 mutations accurately, even though we have not encountered such cases.
The histological type of cancer in all the dMMR cases detected by us was endometrioid adenocarcinoma, among the many histological types of epithelial ovarian cancer. It has been reported that dMMR ovarian cancer is relatively more common among cases of endometrioid adenocarcinoma and clear-cell adenocarcinoma (12, 13) . According to the previous studies (12-16), the incidence of endometrioid adenocarcinoma in ovarian cancers with dMMR was 2.9-18.8%, while we found that 5.4% of the 56 cases of endometrioid adenocarcinoma in our study showed dMMR. HelderWoolderink et al. (35) summarized the histological type in 445 ovarian cancer patients with LS from 49 studies and reported that the most frequently identified histological type was the mixed type (n = 136; 33%), followed by endometrioid adenocarcinoma (n = 103; 25%), serous adenocarcinoma (n = 93; 22%), clear-cell adenocarcinoma (n = 49; 12%) and mucinous adenocarcinoma (n = 18; 4%). Taken together, endometrioid adenocarcinoma may be the histological type of ovarian cancer most frequently associated with dMMR.
In the present study, no pathogenic germline mutations of the genes were detected in any of the cases of dMMR ovarian cancer, indicating that there were no patients with LS among the 305 cases of epithelial ovarian cancer examined. Furthermore, no variants of uncertain significance (VUS) was observed among the three patients examined. According to a recent report (30) , among the 656 epithelial ovarian cancer patients, 4 patients (0.6%) with MSI-H tumors showed pathogenic germline mutations of the MMR genes. The germline mutations in these four patients were observed in the MLH1 (n = 1), MSH2 (n = 1) and MSH6 (n = 2) genes. According to another report (38) , among 1915 patients with epithelial ovarian cancer, pathogenic germline mutations of the MMR genes were detected in 8 patients (0.4%). These mutations were detected in the MLH1, MSH2, MSH6 and PMS2 genes in 1, 0, 3 and 4 patients, respectively. Although these reports are from populations of North America, the prevalence of LS may be a very small number identified by UTS in non-selected patients with epithelial ovarian cancer. Hirasawa et al. (39) have been reported that from Japan pathogenic germline mutations of the MMR genes were detected in 6 patients (2.6%) out of 230 patients with epithelial ovarian cancer. They also reported that MSH6 and PMS2 might be strongly associated with LS. Even in the same country, the prevalence of LS appears to be different between facilities depending on the regionality.
Tumors lacking MMR function include not only those associated with LS, which is characterized by deleterious germline mutation(s) of the MMR genes, but also sporadic cases, in which dMMR is caused by biallelic somatic mutation or hypermethylation of the promoter region of the MLH1 gene (40) . Previous studies on epithelial ovarian cancer (21, 22) have reported a frequency of hypermethylation of the MLH1 promoter region in the range of 12-48%, with higher percentages reported in tumors showing MSI-H. In the present study, in one of the patients showing loss of MLH1/PMS2 in the tumor (Case 1), the dMMR was caused by MLH1 promoter region hypermethylation. This patient could therefore be categorized as having the so-called 'sporadic MSI-H ovarian cancer', just like 'MSI-H colorectal cancer', which is typically caused by hypermethylation of the MLH1 promoter region (41) . Furthermore, patients with Lynch-like syndrome, which could strictly defined as being characterized by biallelic inactivation of the MMR gene(s) in the absence of germline MMR mutation (40) , have recently been identified among patients with colorectal and endometrial cancers (40) . In a study conducted by Buchanan et al. (42) , more than 50% of cases of colorectal and endometrial cancers with MMR deficiency were identified as cases of Lynch-like syndrome. In addition, approximately 50-70% of tumors in patients with Lynch-like syndrome show biallelic pathogenic somatic mutations (43, 44) . In the present study, one of the cases (Case 2) was identified definitively as a case of Lynch-like syndrome, and another (Case 3) could be potentially categorized into Lynch-like syndrome, although we could not determine whether the somatic MMR mutations were biallelic or not because of fragmentation of the DNA in the FFPE sample. We would like to emphasize therefore that patients with Lynch-like syndrome can also be found among patients with epithelial ovarian cancer, just as among patients with colorectal and endometrial cancers. The clinical significance of epithelial ovarian cancer associated with Lynch-like syndrome as compared to that associated with LS remains to be clarified in a future study. Since we found only 3 patients with dMMR among 305 patients with epithelial ovarian cancer, comparison of the clinicopathological characteristics in relation to the MMR status could not be performed in this study. Recently, pembrolizumab, an anti-PD-1 antibody, was approved by the FDA, based on the results of clinical trials, for the treatment of various types of cancers showing loss of MMR expression or MSI-H (4). This drug is expected to improve the overall survival in the subset of cancer patients showing loss of MMR protein expression and/or MSI-H in the tumor (4) . Therefore, the evaluation of MMR protein expression and/or MSI may be required for selecting cancer patients likely to benefit from treatment with pembrolizumab.
There were some limitations in the present study. The study was performed at a single institution. Therefore, there may have been a bias in the selection of patients with epithelial ovarian cancer as the study subjects, although the distributions of the age and histological types were consistent with the respective averages for the Japanese population. Segev et al. (31) reported that in a total of 917 ovarian cancer patients, 21% and 6% of tumors with BRCA1 (n = 29) and BRCA2 (n = 17) mutations showed MSI-H. We did not examine BRCA1 and BRCA2 mutations in this study. Therefore, we cannot deny the possibility that some cases of hereditary breast and ovarian cancer syndrome may have been included in the dMMR epithelial ovarian tumors identified in our study, especially Case 1 had a family history of breast cancer (Table 1 ).
In conclusion, we comprehensively investigate the prevalence of dMMR epithelial ovarian cancer in a Japanese hospital-based population. Moreover, we clarified the molecular mechanisms involved in the dMMR in such tumors. Further accumulation of cases of nonselected dMMR epithelial ovarian cancers will be required to clarify the clinical outcomes, including the efficacy of chemotherapeutic treatment for such tumors.
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